肝细胞肝癌（hepatocellular carcinoma,HCC）（简称肝癌）是常见的转移侵袭性高、耐药性强、复发及致死率高的恶性肿瘤之一。HCC早期无明显特异性症状，常在中晚期或者多部位转移后才被发现，约80%的HCC患者在被诊断时已发生远端转移，因此预后较差。尽管近几十年来在肝癌的诊断和治疗方面不断取得进步，但都不能完全解决其转移复发的问题。目前研究发现，上皮间质转化（epithelial-mesenchymal transition,EMT）在增强肝癌细胞的侵袭转移能力、耐药性及导致肝癌不良预后等方面发挥了重要作用，因此靶向抑制EMT有望成为肝癌治疗的新方向。中药可通过调节EMT的诱导因子及其上游通路来抑制肝癌的转移复发和耐药。本文就EMT的调节机制及其在肝癌中的作用以及中药通过逆转EMT干预治疗肝癌的现状进行综述，以期为肝癌的研究治疗积累理论资料。
Malignant tumor, an important factor threatening human life and health, brings huge economic burden to patients. At present, chemoradiotherapy is still the main treatment method for tumor diseases, but there are also great side effects when it plays a therapeutic role. Traditional Chinese medicine in the prevention and treatment of tumor diseases has many advantages such as few side effects, improving the physiological state of patients, and slowing down the side effects of radiotherapy and chemotherapy. Berberine is an effective component of rhizoma coptidis, with a very good antitumor effect. It can inhibit tumor cell proliferation, promote tumor cell apoptosis, inhibit tumor metastasis and angiogenesis, regulate tumor autophagy, reverse multi-drug resistance of tumor, regulate the body immunity, and affect tumor metabolic reprogramming to play its role. Compared with chemical preparations, berberine has a wide range of sources, with high safety and easy access, and has great potential in the prevention and treatment of malignant tumors. In this article, we would mainly review the research progress on the antitumor mechanism of berberine in recent years.
肺癌是全世界发病率和死亡率最高的恶性肿瘤.非小细胞肺癌是肺癌的主要病理类型,目前治疗以放化疗为主,但患者的5年生存率仍无显著升高.分子靶向治疗是近年来兴起的肺癌治疗方法.肝细胞生长因子受体(c-mesenchymal-epithelia transition factor,c-Met)在肺癌的发生发展过程中发挥着重要作用,可通过影响细胞的增殖、侵袭、转移等促进肿瘤进展,有望成为肺癌分子靶向治疗的新靶点.中药可通过影响c-Met及其下游通路来抑制肺癌的转移复发.本文就c-Met在非小细胞肺癌中的作用及中药干预的研究进行总结综述,为进一步探索肺癌治疗的新方法提供参考.
肝细胞肝癌(hepatocellular carcinoma,HCC)(简称肝癌)是常见的血管侵袭性高、耐药性强的恶性肿瘤之一.CC趋化因子配体20(CC chemokine ligand 20,CCL20)作为一种炎症介质能够诱导肿瘤细胞定向迁移,与其唯一受体趋化因子受体6(chemokine receptor 6,CCR6)结合后激活下游通路,在HCC的发生发展过程中起重要作用.本文介绍了CCL20在HCC进展过程中与上皮间质转化、免疫抑制、血管生成方面的关系;简述了CCL20在其他恶性肿瘤肝转移和HCC预后方面的作用.提示靶向抑制CCL20趋化因子可能在肝细胞肝癌的治疗中具有很好的临床应用前景,以期更好地理解CCL20与HCC之间的关系,为肝细胞肝癌靶向治疗提供新的思路.
